Fluoxetine 10 mg, n20

International Nonproprietary Name (INN): Fluoxetine

Pharmaceutic group: Antidepressants


  • Capsules 10 mg n20;
  • Capsules 20 mg n20.

Available with prescription



Fluoxetine is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001.

Fluoxetine is approved for the treatment of major depression (including pediatric depression), obsessive-compulsive disorder (in both adult and pediatric populations), bulimia nervosa, panic disorder and premenstrual dysphoric disorder. In combination with olanzapine it is known as Symbyax.

Despite the availability of newer agents, fluoxetine remains extremely popular. In 2010, over 24.4 million prescriptions for generic formulations of fluoxetine were filled in the United States alone, making it the third most prescribed antidepressant after sertraline (SSRI; became generic in 2006) and citalopram (SSRI; became generic in 2003).[3]

MEDICAL USES. Fluoxetine is frequently used to treat major depression, obsessive compulsive disorder, bulimia nervosa, panic disorder, body dysmorphic disorder and premenstrual dysphoric disorder. Caution should be taken when using any SSRI for bipolar disorder as this can increase the likelihood of mania; however, fluoxetine can be used with an antipsychotic (such as Quetiapine) for bipolar. It has also been used for cataplexy, obesity, and alcohol dependence, as well as binge eating disorder.

Treatment with fluoxetine should be always controlled by the doctor, who has prescribed the therapy. The medicine is produced in the form of hard gelatin capsules, containing 10 mg or 20 mg of fluoxetine.

DOSING: Depression in adults is treated with 20-80 mg of fluoxetine daily. The recommended dose for treating depression in children is 10-20 mg daily. After 13 weeks of daily administration, once weekly dosing may be effective in some patients.

Bulimia is treated with 60 mg of fluoxetine daily. Long-term treatment for up to 52 weeks has been shown to be beneficial in maintaining remission.

Obsessive-compulsive disorder in adults and children is treated with 20-60 mg daily and panic disorder is managed with 10-60 mg daily. The recommended regimen for PMDD is 20 mg administered every day of the menstrual cycle or daily for 14 days prior to the onset of menstruation through the first day of menses.

The recommended treatment for resistant depressionis 20-50 mg of fluoxetine and 5-20 mg olanzapine once daily in the evening while the recommended treatment for depression associated with bipolar disorder is 20-50 mg fluoxetine and 5-12.5 mg olanzapine once daily in the evening.

DRUG INTERACTIONS: Fluoxetine should not be taken with any of the monoamine oxidase inhibitor (MAOI) class of antidepressants [for example, isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldepryl), and procarbazine (Matulane)] or other drugs that inhibit monoamine oxidase [for example, linezolid (Zyvox)]. Such combinations may lead to confusion, high blood pressure, tremor, hyperactivity, coma, and death. Fluoxetine should not be administered for at least 14 days after stopping MAOIs. Because fluoxetine is active in the body for several weeks, MAOIs should not be administered for at least 5 weeks after fluoxetine has been stopped. Similar reactions occur when fluoxetine is combined with other drugs, for example, tryptophan, St. John's wort, meperidine (Demerol), and tramadol (Ultram) that increase serotonin in the brain.